A lot of your questions will need to wait for the full paper being published as I don’t want to steal the thunder of Nikki’s team so I will avoid commenting on questions 1 to 3.
In regards 4 the independent conditions have been measured, but not all yet.
In answer to question 5, twice a week worked better than once a week. In humans, bisantrene is likely to be used twice in a week once every 4 weeks on a constant background of oral decitabine. The aim is to balance toxicity with anticancer efficacy. Ultimately, the exact protocol used will be up to the investigator.
Ann: Bisantrene shows potent anticancer activity in AML models, page-60
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.33 |
Change
0.015(1.14%) |
Mkt cap ! $224.4M | |||
| Open | High | Low | Value | Volume |
| $1.32 | $1.38 | $1.32 | $71.86K | 53.58K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1121 | $1.33 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.34 | 1700 | 1 |
View Market Depth
| Last trade - 11.20am 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.34 |
Change
0.015 ( 4.69 %) |
||||
| Open | High | Low | Volume | ||
| $1.34 | $1.36 | $1.33 | 3583 | ||
| Last updated 11.22am 10/05/2024 ? | |||||
| RAC (ASX) Chart |